XMT-1522

Dolaflexin-based, cleavable antibody-drug conjugate with a high drug-antibody ratio (DAR)

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	Stomach Neoplasms (Stomach Cancer) 10/01/2019 - "We conclude that XMT-1522 was effective in HER2-positive breast cancer and gastric cancer cell lines resistant to T-DM1, and in xenograft models resistant to T-DM1. " 10/01/2019 - "The effects of XMT-1522 and T-DM1 on cell survival and apoptosis were compared in six HER2-positive breast cancer or gastric cancer cell lines, of which three lines were T-DM1-sensitive (N-87, OE-19, JIMT-1) and three T-DM1-resistant (RN-87, ROE-19, SNU-216). " 10/01/2019 - "A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine."
2.	Breast Neoplasms (Breast Cancer) 10/01/2019 - "We conclude that XMT-1522 was effective in HER2-positive breast cancer and gastric cancer cell lines resistant to T-DM1, and in xenograft models resistant to T-DM1. " 10/01/2019 - "The effects of XMT-1522 and T-DM1 on cell survival and apoptosis were compared in six HER2-positive breast cancer or gastric cancer cell lines, of which three lines were T-DM1-sensitive (N-87, OE-19, JIMT-1) and three T-DM1-resistant (RN-87, ROE-19, SNU-216). "
3.	Neoplasms (Cancer) 10/01/2019 - "The results support the testing of XMT-1522 in clinical trials in patients with HER2-positive cancer." 10/01/2019 - "While RN-87 and JIMT-1 xenograft tumors progressed on T-DM1 treatment, all tumors responded to XMT-1522, and all but one tumor disappeared during the XMT-1522 treatment. "

1.	Immunoconjugates (Immunoconjugate)
2.	Ado-Trastuzumab Emtansine